Sanctuary Advisors LLC Buys New Position in Revvity, Inc. (NYSE:RVTY)

Sanctuary Advisors LLC purchased a new position in shares of Revvity, Inc. (NYSE:RVTY) during the fourth quarter, Holdings Channel.com reports. The fund purchased 1,872 shares of the company’s stock, valued at approximately $209,000.

Other hedge funds have also made changes to their positions in the company. Empirical Finance LLC raised its stake in shares of Revvity by 2.0% in the third quarter. Empirical Finance LLC now owns 4,237 shares of the company’s stock valued at $541,000 after acquiring an additional 85 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in Revvity by 2.4% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 4,214 shares of the company’s stock worth $470,000 after purchasing an additional 100 shares during the period. HB Wealth Management LLC raised its position in Revvity by 4.6% in the 4th quarter. HB Wealth Management LLC now owns 2,380 shares of the company’s stock valued at $266,000 after purchasing an additional 104 shares in the last quarter. Westside Investment Management Inc. boosted its stake in shares of Revvity by 0.8% in the 4th quarter. Westside Investment Management Inc. now owns 14,363 shares of the company’s stock valued at $1,603,000 after buying an additional 108 shares during the period. Finally, Coldstream Capital Management Inc. grew its position in shares of Revvity by 5.1% during the third quarter. Coldstream Capital Management Inc. now owns 2,247 shares of the company’s stock worth $286,000 after buying an additional 110 shares in the last quarter. Institutional investors and hedge funds own 86.65% of the company’s stock.

Insider Activity at Revvity

In related news, insider Tajinder S. Vohra sold 5,492 shares of the business’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $116.81, for a total value of $641,520.52. Following the transaction, the insider now owns 19,652 shares in the company, valued at $2,295,550.12. The trade was a 21.84 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Joel S. Goldberg sold 15,170 shares of the company’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $126.73, for a total value of $1,922,494.10. Following the sale, the insider now directly owns 33,400 shares of the company’s stock, valued at approximately $4,232,782. This represents a 31.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.60% of the stock is owned by insiders.

Revvity Stock Performance

Shares of RVTY stock opened at $111.81 on Thursday. The stock’s 50-day moving average is $116.77 and its two-hundred day moving average is $118.29. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.03 and a current ratio of 3.60. Revvity, Inc. has a 1 year low of $97.32 and a 1 year high of $129.50. The firm has a market cap of $13.43 billion, a price-to-earnings ratio of 50.59, a PEG ratio of 3.82 and a beta of 1.03.

Revvity (NYSE:RVTY) last released its quarterly earnings results on Friday, January 31st. The company reported $1.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.37 by $0.05. Revvity had a return on equity of 7.68% and a net margin of 9.81%. During the same quarter in the prior year, the firm posted $1.25 EPS. Analysts predict that Revvity, Inc. will post 4.94 earnings per share for the current year.

Revvity Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 9th. Stockholders of record on Friday, April 18th will be issued a $0.07 dividend. The ex-dividend date of this dividend is Thursday, April 17th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.25%. Revvity’s payout ratio is 12.67%.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. Sanford C. Bernstein cut shares of Revvity from an “outperform” rating to a “market perform” rating and set a $130.00 target price on the stock. in a report on Friday, January 10th. KeyCorp increased their price objective on shares of Revvity from $132.00 to $145.00 and gave the company an “overweight” rating in a research report on Monday, February 3rd. Bank of America raised shares of Revvity from a “neutral” rating to a “buy” rating and set a $138.00 price objective for the company in a research report on Friday, December 13th. Barclays increased their target price on Revvity from $135.00 to $140.00 and gave the company an “overweight” rating in a report on Monday, February 3rd. Finally, Raymond James reaffirmed an “outperform” rating and set a $145.00 price target (up from $140.00) on shares of Revvity in a report on Monday, February 3rd. Four investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Revvity has a consensus rating of “Moderate Buy” and a consensus target price of $136.25.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.